Cortisol-blocking drug Korlym shows promise for stubborn diabetes and hypertension

New research suggests that high cortisol levels may worsen type 2 diabetes and resistant hypertension. Corcept Therapeutics has presented findings showing that its cortisol-blocking drug, Korlym, could help patients who struggle with these conditions. The data were shared at the American Diabetes Association’s 86th Scientific Sessions. The company’s studies, CATALYST and MOMENTUM, examined patients with hard-to-control diabetes and high blood pressure. In CATALYST, 24% of participants with poorly managed type 2 diabetes had hypercortisolism. The MOMENTUM trial revealed a similar pattern: 27.3% of those with resistant hypertension also showed elevated cortisol levels. These patients were often taking multiple blood pressure medications and had type 2 diabetes.

In the CATALYST trial, participants with hypercortisolism received either Korlym or a placebo. Those on Korlym saw a significant drop in HbA1c levels—an average reduction of 1.3%. Their body weight fell by 5.1 kg, BMI decreased by 1.7 kg/m², and waist size shrank by 5.1 cm. The improvements were far greater than in the placebo group.

The drug appeared even more effective when combined with GLP-1 receptor agonists or tirzepatide. Patients on these additional treatments experienced even larger reductions in HbA1c, weight, BMI, and waist circumference. The findings suggest Korlym may enhance the effects of existing diabetes therapies.

Corcept Therapeutics specialises in drugs that modulate cortisol, a hormone linked to severe metabolic, endocrine, and neurological disorders. The company’s research indicates that excess cortisol could be a hidden factor in treatment-resistant cardiometabolic diseases. The results highlight Korlym’s potential as an add-on therapy for patients with uncontrolled diabetes and high cortisol levels. When paired with GLP-1 drugs or tirzepatide, it may offer stronger benefits in lowering blood sugar, weight, and other key health markers. Further studies could explore its role in managing resistant hypertension and metabolic disorders.